We assign a fundamental rating of 1 out of 10 to GELS. GELS was compared to 190 industry peers in the Pharmaceuticals industry. GELS may be in some trouble as it scores bad on both profitability and health. GELS does not seem to be growing, but still is valued expensively.

Quickly go to:

1. Profitability

2. Health

3. Growth

4. Valuation

5. Dividend

1. Profitability

1.1 Basic Checks

GELS had negative earnings in the past year.
GELS had a negative operating cash flow in the past year.
In the past 5 years GELS always reported negative net income.
GELS had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

GELS's Return On Assets of -30.94% is in line compared to the rest of the industry. GELS outperforms 51.31% of its industry peers.
GELS has a Return On Equity (-42.05%) which is comparable to the rest of the industry.

		Industry Rank	Sector Rank
ROA	-30.94%
ROE	-42.05%
ROIC	N/A

ROA(3y)-21.21%

ROA(5y)-16.14%

ROE(3y)-28.1%

ROE(5y)-20.64%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

The Gross Margin of GELS (30.36%) is comparable to the rest of the industry.
In the last couple of years the Gross Margin of GELS has declined.
The Profit Margin and Operating Margin are not available for GELS so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	30.36%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y-5.29%

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

GELS does not have a ROIC to compare to the WACC, probably because it is not profitable.
GELS has more shares outstanding than it did 1 year ago.
GELS has a worse debt/assets ratio than last year.

2.2 Solvency

GELS has an Altman-Z score of -0.45. This is a bad value and indicates that GELS is not financially healthy and even has some risk of bankruptcy.
GELS has a Altman-Z score (-0.45) which is comparable to the rest of the industry.
A Debt/Equity ratio of 0.00 indicates that GELS is not too dependend on debt financing.
GELS has a better Debt to Equity ratio (0.00) than 62.30% of its industry peers.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Altman-Z	-0.45

ROIC/WACCN/A

WACC8.5%

2.3 Liquidity

A Current Ratio of 0.27 indicates that GELS may have some problems paying its short term obligations.
Looking at the Current ratio, with a value of 0.27, GELS is doing worse than 94.24% of the companies in the same industry.
GELS has a Quick Ratio of 0.27. This is a bad value and indicates that GELS is not financially healthy enough and could expect problems in meeting its short term obligations.
The Quick ratio of GELS (0.27) is worse than 92.67% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	0.27
Quick Ratio	0.27

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The earnings per share for GELS have decreased strongly by -87.41% in the last year.
Measured over the past years, GELS shows a small growth in Revenue. The Revenue has been growing by 3.95% on average per year.

EPS 1Y (TTM)-87.41%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-486.26%

Revenue 1Y (TTM)N/A

Revenue growth 3Y3.95%

Revenue growth 5YN/A

Sales Q2Q%N/A

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

EPS Next YN/A

EPS Next 2YN/A

EPS Next 3YN/A

EPS Next 5YN/A

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.